Targeted therapy for non-small-cell lung cancer

Abstract

Get full access to this article

View all access options for this article.

References

Parkin

Bray

Ferlay

Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74–108. doi:10.3322/canjclin.55.2.74

Lynch

Bell

Sordella

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129–39. doi:10.1056/NEJMoa040938

Hirsch

Varella-Garcia

Bunn

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:5034– 42. doi:10.1200/JCO.2006.06.3958

Tamura

Okamoto

Kashii

Multicentre prospective phase II trial of gefitinib for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008; 98:907–14. doi:10.1038/sj.bjc.6604249

Mitsudomi

Morita

Yatabe

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121–8. doi:10.1016/S1470-2045(09)70364-X